OTCMKTS:KHTRF

Knight Therapeutics Stock Forecast, Price & News

$4.20
-0.02 (-0.47 %)
(As of 04/12/2021 11:45 AM ET)
Add
Compare
Today's Range
$4.20
Now: $4.20
$4.20
50-Day Range
$3.95
MA: $4.18
$4.43
52-Week Range
$3.95
Now: $4.20
$5.69
Volume400 shs
Average Volume30,700 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; NERLYNX for the treatment of HER2-positive breast cancer; and Trelstar for prostate cancer. It also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; NeurAxon family for acute migraine, pain and neurological disorders; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to tre Ibsrela at tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; Burinex for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease; Impavido, an oral drug treatment based on miltefosine for the visceral, cutaneous, and mucocutaneous leishmaniasis; and Imvexxy for moderate-to-severe dyspareunia and Bijuva for moderate-to-severe vasomotor symptoms due to menopause. It develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. It develops TULSA-PRO, a medical device for prostate ablation. It finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:KHTRF
CUSIPN/A
CIKN/A
Phone(514) 484-4483
Employees48
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings Date6/24/2021 (Estimated)
OptionableNot Optionable

Headlines

Here's what Wall Street expects from Knight Therapeutics's earnings
March 25, 2021 |  markets.businessinsider.com
Knight Announces Filing of Preliminary Base Shelf Prospectus
December 10, 2020 |  finance.yahoo.com
Knight Therapeutics Reports Third Quarter 2020 Results
November 13, 2020 |  finance.yahoo.com
Knight Therapeutics Inc. (KHTRF)
October 8, 2020 |  in.finance.yahoo.com
Health Canada OK's Knight and TherapeuticsMD for BIJUVA
September 21, 2020 |  seekingalpha.com
Why Knight Therapeutics' (TSE:GUD) CEO Pay Matters
August 18, 2020 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.22 out of 5 stars

Medical Sector

887th out of 2,016 stocks

Drug Manufacturers - Specialty & Generic Industry

13th out of 61 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$4.20
-0.02 (-0.47 %)
(As of 04/12/2021 11:45 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KHTRF News and Ratings via Email

Sign-up to receive the latest news and ratings for KHTRF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Knight Therapeutics (OTCMKTS:KHTRF) Frequently Asked Questions

Is Knight Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Knight Therapeutics stock.
View analyst ratings for Knight Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Knight Therapeutics?

Wall Street analysts have given Knight Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Knight Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Knight Therapeutics?

Knight Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 1,408,000 shares, a drop of 26.0% from the February 28th total of 1,902,200 shares. Based on an average daily trading volume, of 4,300 shares, the short-interest ratio is currently 327.4 days.
View Knight Therapeutics' Short Interest
.

When is Knight Therapeutics' next earnings date?

Knight Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, June 24th 2021.
View our earnings forecast for Knight Therapeutics
.

How has Knight Therapeutics' stock price been impacted by COVID-19?

Knight Therapeutics' stock was trading at $4.7934 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KHTRF shares have decreased by 12.4% and is now trading at $4.2011.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for KHTRF?

3 analysts have issued 1 year price targets for Knight Therapeutics' shares. Their forecasts range from $6.75 to $10.50. On average, they expect Knight Therapeutics' share price to reach $8.00 in the next year. This suggests a possible upside of 90.4% from the stock's current price.
View analysts' price targets for Knight Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Knight Therapeutics' key executives?

Knight Therapeutics' management team includes the following people:
  • Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A., BA, LLB, MBA, Founder, CEO & Director (Age 52)
  • Ms. Samira Sakhia BCom, MBA, CPA, CA, Pres & Director (Age 53)
  • Mr. Arvind Utchanah, Chief Financial Officer
  • Ms. Amal Khouri M.B.A., VP of Bus. Devel.
  • Ms. Jody Engel, Sr. Director of Bus. Devel.
  • Mr. Michel Loustric, Pres of Knight Barbados

Who are some of Knight Therapeutics' key competitors?

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the OTCMKTS under the ticker symbol "KHTRF."

How do I buy shares of Knight Therapeutics?

Shares of KHTRF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Knight Therapeutics' stock price today?

One share of KHTRF stock can currently be purchased for approximately $4.20.

How many employees does Knight Therapeutics have?

Knight Therapeutics employs 48 workers across the globe.

What is Knight Therapeutics' official website?

The official website for Knight Therapeutics is www.gud-knight.com.

How can I contact Knight Therapeutics?

The company can be reached via phone at (514) 484-4483.


This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.